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Introduction
Human exposure to phthalates is widespread 
[Centers for Disease Control and Prevention 
(CDC) 2015]. Phthalates are used to increase 
the flexibility of certain plastics and can also 
be found in pharmaceuticals, personal care 
products, paints, toys, medical devices, and 
building supplies (CDC 2015). Phthalates 
may diffuse into their surroundings, and 
exposure normally occurs through ingestion 
of contaminated food, dermal application of 
lotions or perfumes, or inhalation.
Animal studies have suggested that phthal-
ates can decrease fertility and litter size, and 
interfere with development of the offspring 
(Gray et al. 2006; Yamasaki et al. 2009). 
The mechanism for these effects may involve 
lower production of estradiol or progesterone 
(Kay et al. 2013). In humans, most studies 
have focused on pregnancy and offspring 
outcomes, with fewer studies on intermediate 
measures of reproductive function.
Recently, mono(2-ethylhexyl) phthalate 
(MEHP), a metabolite of di(2-ethylhexyl) 
phthalate (DEHP), was shown to stimu-
late oxidative stress responses in human 
placental cells (Tetz et al. 2013). This is 
further supported by data from the National 
Health and Nutrition Examination Survey 
(NHANES) suggesting that several phthalate 
metabolites are associated with markers of 
oxidative stress or inflammation (Ferguson 
et al. 2011, 2012, 2014). In the only published 
study of naturally conceived pregnancies, 
urinary MEHP was associated with increased 
risk of early pregnancy loss in a prospective 
cohort study of 128 Danish women who had 
32 early pregnancy losses (Toft et al. 2012).
Exposure to bisphenol A (BPA), another 
environmental chemical, is also widespread 
(CDC 2015). Animal data suggest that BPA 
reduces female fertility (Berger et al. 2007, 
2008, 2010; CDC 2015; Takai et al. 2001; 
Tsutsui et al. 1998). Evidence suggests 
that oral BPA exposure disrupts meiosis 
in vitro (Can et al. 2005; Lenie et al. 2008; 
Machtinger et al. 2011) and in vivo (Hunt 
et al. 2003; Muhlhauser et al. 2009). Among 
women undergoing in vitro fertilization, 
urinary BPA concentration was associated 
with reduced peak estradiol, oocyte yield, and 
oocyte quality (Ehrlich et al. 2012; Mok-Lin 
et al. 2010). However, data are lacking for 
women who conceive without intervention.
Phthalates and BPA may reduce fecund-
ability through several mechanisms, including 
ovulation, conception, and subclinical preg-
nancy loss. Therefore, we explored possible 
adverse effects that could be exerted through 
lengthened follicular phase or shortened 
luteal phase, increased time to pregnancy, 
or increased early pregnancy loss. These 
end points were examined in relation to 
menstrual cycle–specific urinary concentra-
tions of phthalate metabolites and BPA in 
a cohort of women who were attempting to 
become pregnant naturally. Given the previ-
ously described literature, we focused on the 
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Background: Certain phthalates and bisphenol A (BPA) show reproductive effects in animal 
studies and potentially affect human ovulation, conception, and pregnancy loss.
oBjectives: We investigated these chemicals in relation to follicular- and luteal-phase lengths, time 
to pregnancy, and early pregnancy loss (within 6 weeks of the last menstrual period) among women 
attempting pregnancy.
Methods: Women discontinuing contraception provided daily first-morning urine specimens and 
recorded days with vaginal bleeding for up to 6 months. Specimens had previously been analyzed 
for estrogen and progesterone metabolites and human chorionic gonadotropin. A total of 221 
participants contributed 706 menstrual cycles. We measured 11 phthalate metabolites and BPA in 
pooled urine from three specimens spaced throughout each menstrual cycle. We analyzed associa-
tions between chemical concentrations and outcomes using linear mixed models for follicular- and 
luteal-phase lengths, discrete-time fecundability models for time to pregnancy, and logistic regres-
sion for early pregnancy loss.
results: Higher concentrations of monocarboxyoctyl phthalate (MCOP) were associated with 
shorter luteal phase [2nd tertile vs. 1st tertile: –0.5 days (95% CI: –0.9, –0.1), 3rd vs. 1st: –0.4 days 
(95% CI: –0.8, 0.01), p = 0.04]. BPA was also associated with shorter luteal phase [2nd vs. 1st: 
–0.8 days (95% CI: –1.2, –0.4), 3rd vs. 1st: –0.4 days (95% CI: –0.8, 0.02), p = 0.001].
conclusions: BPA and MCOP (or its precursors) were associated with shorter luteal phase. 
Menstrual cycle–specific estimates of urinary BPA and phthalate metabolites were not associated 
with detrimental alterations in follicular-phase length, time to pregnancy, or early pregnancy 
loss, and in fact, DEHP [di(2-ethylhexyl) phthalate] metabolites {MEOHP [mono(2-ethyl-5-
oxohexyl) phthalate] and ∑DEHP} were associated with reduced early loss. These findings should 
be confirmed in future human studies.
citation: Jukic AM, Calafat AM, McConnaughey DR, Longnecker MP, Hoppin JA, Weinberg CR, 
Wilcox AJ, Baird DD. 2016. Urinary concentrations of phthalate metabolites and bisphenol A and 
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metabolites of DEHP and BPA as potential 
risk factors for increased early loss. To our 
knowledge, this study represents the first 
study of BPA and early human pregnancy in a 
cohort of naturally conceiving women.
Methods
Study sample. The North Carolina Early 
Pregnancy Study (EPS) was a prospective 
cohort study designed to estimate the inci-
dence of early pregnancy loss (Wilcox et al. 
1988b). Briefly, 221 healthy women with no 
known fertility problems or chronic health 
conditions were recruited in 1982–1986 from 
local communities and enrolled at the time 
they discontinued contraception to become 
pregnant. An in-person interview at enroll-
ment collected information on women’s 
demographic, reproductive, medical, and 
behavioral characteristics, including their 
age, education, and body weight. Women 
reported their weekly intake of beer, wine, or 
hard liquor, caffeinated coffee, tea and iced 
tea, and caffeinated sodas. Women who were 
still in the study 3 months after enrollment 
were asked again about their alcohol and 
caffeine intake. 
Participants collected first-morning 
urine specimens and completed daily diaries, 
until a clinical pregnancy was conceived 
or 6 months had passed with no clinically 
recognized pregnancy. Nineteen women 
withdrew from the study before completing 
the 6-month follow-up. Data collected during 
their participation are included in these 
analyses. Urine specimens were collected in 
30-mL wide-mouth polypropylene jars with 
screw tops and without preservatives. They 
were stored for up to 2 weeks in participants’ 
home freezers. Samples were transported to a 
central storage unit in insulated chests with 
ice packs and stored at –20°C. Specimens 
were analyzed for reproductive hormones (see 
below for a detailed description) and then 
transferred to long-term storage vials (first 
glass, then polypropylene). Care was taken to 
keep the samples frozen throughout transport. 
New aliquots were drawn from these stored 
samples for phthalate and BPA measurement. 
Each participant provided written informed 
consent, and the study protocol was approved 
by the Institutional Review Board of the 
National Institute of Environmental Health 
Sciences. The analysis of blinded specimens 
by the CDC laboratory was determined 
not to constitute engagement in human 
subjects research.
Outcome measures. Daily urine speci-
mens were assayed previously for estrone 
3-glucuronide (a metabolite of estrogen) 
and pregnanediol 3-glucuronide (a metabo-
lite of progesterone). These data were used 
to identify the day of ovulation (or anovu-
lation, if no ovulation was detected) (Baird 
et al. 1991). Follicular-phase length was 
defined as the number of days from the first 
day of menses (based on the bleeding pattern 
recorded in the daily diary) up to but not 
including the estimated day of ovulation 
(n = 675). Luteal-phase length was defined as 
the number of days from the day after ovula-
tion up to, but not including, the first day of 
the subsequent menses (n = 482).
Urine specimens were assayed for human 
chorionic gonadotropin (hCG) (Wilcox et al. 
1988a). Pregnancy was identified by an hCG 
level exceeding 0.025 ng/mL on 3 consecutive 
days. If hCG subsequently declined before 
6 completed weeks of gestation (42 days), it 
was considered an early pregnancy loss. There 
were 48 early pregnancy losses detected and 
150 clinical conceptions (conceptions lasting 
> 6 weeks), of which 15 ended in clinical 
miscarriage (6–25 gestational weeks).
We measured time to pregnancy as the 
number of ovulatory menstrual cycles from 
enrollment to conception (including the 
conception cycle), with censoring at the 
time collection was discontinued. The 221 
participants in the study contributed a total 
of 740 menstrual cycles, of which 706 are 
included in this analysis (see Supplemental 
Material, Table S1).
Sample size. Seven anovulatory cycles were 
excluded, as were 27 cycles in which there 
was no unprotected intercourse during the 
6-day fertile window (Wilcox et al. 1995). 
Cycles for which we could not identify a day 
of ovulation were included if intercourse 
occurred 12–19 days before the start of the 
next cycle (n = 28). There were 706 cycles 
in the time-to-pregnancy analysis. The cycles 
missing day of ovulation (n = 28) provided 
no data on follicular- or luteal-phase lengths, 
leaving 678 cycles for analysis. Furthermore, 
because conception interferes with subse-
quent menstrual bleeding, luteal-phase length 
could not be defined for the 191 conception 
cycles, which included 48 early losses. In three 
women, two ovulations occurred with no 
reported menses in between. Each ovulation 
was considered its own cycle; however, the 
first cycle was missing a luteal-phase length 
and the second cycle was missing a follicular-
phase length, leaving 675 follicular phases and 
484 luteal phases. Finally, two women did not 
have an end date for the last cycle in the study, 
leaving 482 luteal phases for analysis.
Phthalate metabolites and BPA measures. 
We tested the potential for using stored EPS 
urine samples to examine associations of BPA 
and phthalate metabolite concentrations with 
reproductive outcomes. Published results 
from those pilot studies (Baird et al. 2010; 
Nepomnaschy et al. 2009) describe the basis 
for using EPS urine samples in a full analysis 
(described here). Briefly, we found that the 
mean and distribution of BPA were similar to 
those of the first available NHANES samples 
collected in 2003–2004, and concentrations 
of the phthalate metabolites in EPS samples 
tended to be higher than for the first 1999–
2002 NHANES samples (CDC 2015), but 
the relative ranking of the phthalate metabo-
lites changed little between sampling periods. 
In addition, the metabolites of DEHP were 
highly correlated, as they are in samples 
collected after 2000, such as NHANES 
(Baird et al. 2010; CDC 2015). Most impor-
tant, the reproducibility of samples drawn 2 
or 4 weeks apart was similar to reproducibility 
reported for samples collected after 2000. 
These comparisons suggest long-term stability 
of both BPA and phthalate metabolites 
across the past 25 years (Baird et al. 2010; 
Nepomnaschy et al. 2009).
Urine specimen selection. Monday urine 
specimens were used in most cases because 
women collected two vials on Mondays, 
providing twice the volume of sample on 
those days. However, when those samples 
were missing (or the cycle was too short), 
we substituted an available sample from 
another day of the week. Of the urine speci-
mens used in the pooled samples, 14% were 
non-Monday specimens (104 of the 706 
cycle-specific pooled samples included at 
least one non-Monday aliquot). Menstrual 
cycle phase was not associated with urinary 
phthalate metabolite or BPA concentra-
tions in previous analyses (Baird et al. 2010; 
Nepomnaschy et al. 2009). Women could 
have been pregnant when the luteal-phase 
specimen was collected. However, pregnan-
cies took at least 6 days to implant (most 
took 8–10 days), so it is unlikely that the 
pregnancy had implanted in the uterus at the 
time the sample had been collected. This also 
suggests that the pregnancy had little time to 
potentially affect the measured concentrations 
of BPA or phthalate metabolites. Occasionally 
women collected their urine specimen later in 
the day. Of the urine specimens chosen for 
phthalate metabolite and BPA measurements, 
only 5% were late voids, and thus we refer to 
the samples as “first-morning.”
Three urine specimens were chosen from 
each menstrual cycle, including at least one 
specimen from the luteal phase. A fixed-
volume aliquot was taken from each urine 
specimen, and the three aliquots from each 
cycle were pooled to provide a more stable 
exposure measure summarizing the cycle. 
After deconjugation, we measured the 
total urinary concentration of BPA and of 
phthalate metabolites in the pooled urine 
sample using online solid phase–extraction, 
high-performance liquid chromatography–
isotope dilution tandem mass spectrometry 
at CDC (Silva et al. 2007; Ye et al. 2005). To 
explore the possibility of contamination, we 
analyzed 10 random individual samples for 
Phthalates, BPA, and reproductive toxicity
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free and total concentrations of BPA. We did 
not detect free BPA in 9 of the samples; in 
1, the BPA concentrations (free, 2.1 ng/mL; 
total, 2.9 ng/mL) were suggestive of possible 
contamination or degradation.
Measurement of phthalate metabolites 
is preferred to measurement of the parent 
compounds because contamination of the 
sample by parent compounds is not expected 
to significantly increase metabolite levels; 
also, phthalate metabolites are considered 
the biologically active molecules (Hauser 
and Calafat 2005). The phthalate metabo-
lites measured in this study are those typically 
measured in NHANES and other epide-
miologic studies and are listed in Table 1. 
We calculated the molar sum (in nanomoles 
per milliliters) of the DEHP metabolites 
(ΣDEHP): MEHP, mono(2-ethyl-5-oxo-
hexyl) phthalate (MEOHP), mono(2-ethyl-
5-hydroxyhexyl) phthalate (MEHHP), and 
mono(2-ethyl-5-carboxypentyl) phthalate 
(MECPP). None of the measurements from 
the pooled specimens were below the limits 
of detection (LODs). LODs were 0.5 ng/mL 
for MEHP, 0.4 ng/mL for mono-n-butyl 
phthalate (MnBP), monoethyl phthalate 
(MEP), and BPA, 0.3 ng/mL for mono-
iso-butyl phthalate (MiBP), and 0.2 ng/mL 
for the remaining metabolites. All measures 
were standardized by the creatinine concen-
tration measured in the pooled specimen. 
For comparison, we calculated the median 
and interquartile range of urinary phthalate 
metabolites and BPA measured in the 
2009–2010 NHANES [National Center for 
Health Statistics (NCHS) 2011a, 2011b]. 
The estimates were weighted using the 
NHANES examination sample weights to 
produce national estimates and to adjust for 
the complex sample design of NHANES.
Before carrying out tests of association, 
we used Akaike’s Information Criterion to 
decide for each phthalate metabolite and BPA 
whether to model it in tertiles or as linear, 
quadratic, or a spline predictor, based on 
goodness of fit of the unadjusted associations. 
This vetting procedure led to tertile analysis 
for all models.
Analysis. We analyzed the relation 
between the natural logarithm of follicular-
phase length (to achieve normality) and BPA 
and phthalate metabolites urinary concen-
trations (untransformed) measured during 
a given menstrual cycle using linear mixed 
models with a random intercept for each 
woman to account for dependence among 
cycles within each woman. The same models 
were used to analyze the association between 
luteal-phase length (untransformed) and 
BPA and phthalate metabolite concentra-
tions. We exponentiated the beta estimates 
from the follicular-phase model (given that it 
was log-transformed) to obtain the “percent 
difference” between each of the higher tertiles 
and the lowest (referent) tertile.
Time to pregnancy is inversely related to 
fecundability (defined as the probability of 
conceiving a pregnancy in a given menstrual 
cycle) (Baird et al. 1986). Time to pregnancy 
was measured as the number of menstrual 
cycles until a clinical conception was achieved 
(it included cycles of early loss, which was 
studied as a separate outcome). We compared 
fecundability across cycle-specific concen-
trations of phthalate metabolites and BPA 
using fecundability ratios, estimated from a 
discrete-time hazard model of time to preg-
nancy (Weinberg and Wilcox 2008). Data 
were censored at the end of participation 
for those who had not conceived a clinical 
pregnancy. This analysis identifies differences 
in cycle-specific phthalate concentrations for 
conception cycles compared with noncon-
ception cycles across each cycle of trying (as 
a “between-women” analysis). We checked 
the proportional-hazards assumption by 
testing interactions with time; none had a 
p-value < 0.1. The number of cycles contrib-
uted by each woman ranged from 1 to 9 (see 
Supplemental Material, Table S1); however, 
only one woman had an eighth and ninth 
cycle of observation, so these cycles were 
collapsed down and analyzed with the seventh 
cycles to avoid inestimable parameters.
In a secondary analysis, we also compared 
BPA and phthalate metabolite concentrations 
for nonconception and clinical conception 
cycles within each woman. This analysis 
was limited to women who had at least one 
nonconception cycle and a clinical preg-
nancy in the study (n = 94). These matched 
sets were analyzed with conditional logistic 
regression. Given the smaller sample size and 
the necessary exclusion of the most and least 
fertile couples, we consider this analysis to be 
secondary to the between-women analysis.
The associations of conception-cycle 
phthalate metabolite and BPA concentrations 
with early pregnancy loss were analyzed using 
unconditional logistic regression.
For all outcomes, unless otherwise noted, 
p-values represent 2-degrees-of-freedom (df) 
tests of differences among the tertiles. Linear 
trend p-values were obtained post hoc for 
exposures showing increasing or decreasing 
estimates across tertiles. We fitted a linear 
coefficient to the tertiles and performed a 1-df 
test on that parameter. In all analyses, p ≤ 0.05 
was considered statistically significant.
Potential covariates for the analysis of 
each outcome were chosen considering our 
previous analyses of EPS data and other litera-
ture on these outcomes. The chosen adjust-
ment factors were entered into multivariable 
models, and only variables that were associ-
ated with the outcome (p < 0.1) or improved 
point estimate precision were retained. For 
follicular-phase length (Jukic et al. 2007), 
we adjusted for age (continuous), alcohol 
intake (in three categories based on the 25th 
and 75th percentiles), and recent use of oral 
contraceptives (within 90 days of menstrual 
cycle start). Body mass index (BMI) was not 
associated with follicular-phase length in 
the full models, and its exclusion improved 
precision; thus, BMI was not included in the 
final models.
The covariates for the analysis of luteal-
phase length (Fenster et al. 1999; Windham 
et al. 2002) were age (continuous) and BMI 
(in categories: < 20, 20–25, > 25). Caffeine, 
alcohol, and smoking were not associated 
with luteal-phase length in the full models 
and were removed to improve the precision of 
the estimates.
The covariates for the time-to-pregnancy 
analysis (Weinberg et al. 1989; Wilcox et al. 
1988a) were age, age at menarche (in three 
categories), smoking at enrollment (yes/no), 
alcohol intake (in three categories based on 
the 25th and 75th percentiles), BMI, caffeine 
consumption (in three categories based on the 
25th and 75th percentiles), and education. 
Alcohol and caffeine use were time-dependent 
variables, with cycles of attempt of three or 
more assigned the alcohol and caffeine intake 
levels reported on the 3-month questionnaire. 
We found no association of season of the 
year with fecundability (p = 0.83), and season 
was therefore not included in the multivari-
able model. In utero exposure to maternal 
Table 1. Phthalate metabolites measured in pooled urine samples from EPS participants.
Phthalate metabolite Abbreviation Parent compound
Parent compound 
abbreviation
Mono-n-butyl phthalate MnBP Di-n-butyl phthalate DnBP
Monoethyl phthalate MEP Diethyl phthalate DEP
Monobenzyl phthalate MBzP benzylbutyl phthalate BzBP
Mono(2-ethylhexyl) phthalate MEHP Di(2-ethylhexyl) phthalate DEHP
Mono(2-ethyl-5-hydroxyhexyl) phthalate MEHHP Di(2-ethylhexyl) phthalate DEHP
Mono(2-ethyl-5-oxohexyl) phthalate MEOHP Di(2-ethylhexyl) phthalate DEHP
Mono(2-ethyl-5-carboxypentyl) phthalate MECPP Di(2-ethylhexyl) phthalate DEHP
Monocarboxynonyl phthalate MCNP Di-isodecyl phthalate DiDP
Monocarboxyoctyl phthalate MCOP Di-isononyl phthalate DiNP
Mono(3-carboxypropyl) phthalate MCPP Di-n-octyl phthalate DOP
Di-n-butyl phthalate DnBP
Mono-isobutyl phthalate MiBP Di-isobutyl phthalate DiBP
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smoking was missing for 16% of cycles, and 
adjustment did not change the presented 
conclusions, so it was not included in the 
final models. No covariates were included 
in the comparison of nonconception and 
conception cycles within women because 
we had limited information on time-varying 
covariates, and the number of women in this 
analysis was small.
The covariates for the analysis of early 
pregnancy loss (Weinberg et al. 1994; Wilcox 
et al. 1990) were age, current smoking, 
alcohol intake, BMI, caffeine consumption, 
education, and season of conception. Season 
of conception was analyzed with trigono-
metric regression, converting the date of 
ovulation to radians and calculating the sine 
and cosine of this angle (Galbraith 2014). 
Excluding women who reported in utero 
exposure to diethylstilbestrol (n = 5) did not 
substantially alter the estimates, thus these 
women were included in the final model.
In adult female mice, the adverse effects 
of environmentally relevant doses of BPA on 
meiosis were strongest for BPA administra-
tion during oocyte growth, which begins 
2–3 estrus cycles before ovulation (Hunt 
and Hassold 2008; Hunt et al. 2003). 
Oocyte growth in humans is also prolonged, 
with a mean time of 3.5 cycles from prean-
tral follicle to ovulation (Greenwald and 
Terranova 1988). For this reason, we 
performed a sensitivity analysis examining a 
1-cycle lag in BPA concentrations—BPA in 
1 cycle with luteal-phase length, follicular-
phase length, early loss or conception in the 
subsequent cycle. Additionally, to follow up 
on our present findings with luteal-phase 
length, we examined the association of BPA 
and monocarboxyoctyl phthalate (MCOP) 
with low mid-luteal progesterone (< 2 μg/
mg creatinine). Mid-luteal progesterone 
was defined as the geometric mean of the 
urinary progesterone metabolite on days 5 
and 6 postovulation (Baird et al. 1999). This 
measure was associated with reduced fecund-
ability in a previous analysis (Baird et al. 
1999). We used generalized estimating equa-
tions to estimate the associations of both BPA 
and MCOP with low mid-luteal progesterone, 
while accounting for the correlation among 
cycles within each woman.
Results
The median age of participants was 29 years 
(interquartile range, 26–31); most were 
white (96%), college graduates, parous, 
and with a BMI of 20–25 kg/m2 (see 
Supplemental Material, Table S2). Few were 
smokers (n = 15). Consumption of alcohol 
or caffeinated beverages was moderate, with 
almost 30% of women reporting no alcohol 
consumption and 50% reporting ≤ 120 mg of 
caffeine per day.
Compa r ed  w i th  NHANES  da t a 
(2009–2010), women in the EPS (1982–1986) 
showed higher concentrations of most urinary 
phthalate metabolites and BPA (Table 2). 
MEP had the highest concentration in the EPS 
women, followed by MnBP and the DEHP 
metabolites. Concentrations of MEHP were 
higher in the Danish women in 1992–1994 
[the prior study that examined early pregnancy 
loss (Toft et al. 2012)] than in the EPS or 
NHANES, whereas urinary concentrations of 
MEHHP and MEOHP were similar to those 
in the EPS women (Table 2). BPA was not 
measured in the Danish study.
Follicular-phase length. Neither BPA nor 
any of the phthalate metabolites was associ-
ated with follicular-phase length (p > 0.05, 
Figure 1). The strongest association was for 
mono(3-carboxypropyl) phthalate (MCPP, 
a nonspecific metabolite of several phthal-
ates). The percent change in follicular-phase 
length [95% confidence interval (CI)], for 
the second tertile versus the first was –5% 
(95% CI: –9, 0), and for the third tertile 
versus the first was –2% (95% CI: –7, 4) 
(differences among tertiles, p = 0.1; Figure 1).
Luteal-phase length. Two phthalate 
metabolites and BPA were significantly asso-
ciated with luteal-phase length (Figure 2). 
For MECPP, the third tertile showed signifi-
cantly longer luteal phases than the second, 
but neither differed significantly from the 
first tertile. Higher urinary concentrations of 
MCOP, a metabolite of di-isononyl phthalate 
(DiNP), were associated with shorter luteal 
phases by about half a day [second tertile vs. 
first tertile: –0.5 days (95% CI: –0.9, –0.1), 
third vs. first: –0.4 days (95% CI: –0.8, 0.01), 
p = 0.03] (Figure 2). Higher BPA concentra-
tion was also associated with shorter luteal 
phases [second vs. first: –0.8 days (95% CI: 
–1.2, –0.4); third vs. first: –0.4 days (95% CI: 
–0.8, 0.02), p = 0.001]. BPA in the previous 
cycle was not associated with luteal-phase 
length (p = 0.91).
Figure 1. Results of the linear mixed-model regres-
sion estimating the associations between urinary 
concentrations of phthalate metabolites and BPA 
and the natural log of follicular-phase length 
among all study cycles (n = 706) (adjusted for age, 
recent oral contraceptive use, and alcohol use). 
Beta coefficients from the regression model have 
been exponentiated, resulting in estimates of the 
relative length of the follicular phase for concen-
trations in the middle (white circles) and highest 
(black circles) tertiles compared with the lowest 
tertile (gray circles). Line segments represent the 
95% CI. p-Values represent a 2-df test of differ-
ence among the tertiles. sum(DEHP) represents 
the molar sum of four of the metabolites of DEHP: 































Table 2. Distribution of phthalate metabolites and bisphenol A urinary concentrations in the North 
Carolina Early Pregnancy Study (EPS) and in comparison populations: U.S. NHANES 2009–2010 and a 
Danish prospective cohort, 1992–1994 (Toft et al. 2012) [median (IQR)].








EPSc (1982–1986)  
(n = 706 total menstrual cycles 
from 221 women)
MnBP 18.2 (7.8, 33.2) 174.1 (106.5, 314.6)d 80.0 (48.7, 127.0)
MEP 68.0 (24.6, 195.0) 223.6 (113.1, 418.7) 134 (72.4, 296.0)
MBzP 6.7 (3.1, 15.3) 12.4 (7.3, 22.9) 39.5 (24.7, 68.6)
MEHP 1.6 (0.66, 3.3) 15.4 (7.5, 26.6) 6.6 (3.8, 11.2)
MEHHP 11.1 (5.1, 21.9) 36.3 (24.5, 57.4) 50.4 (31.8, 80.8)
MEOHP 7.6 (3.4, 14.8) 33.3 (22.2, 49.5) 30.3 (19.5, 48.9)
MECPP 17.8 (8.9, 32.3) Not reported 66.0 (42.2, 100.0)
MCNP 2.6 (1.3, 5.3) Not reported 3.4 (2.1, 6.2)
MCOP 11.2 (4.6, 28.9) Not reported 3.3 (2.3, 5.2)
MCPP 2.6 (1.3, 5.9) Not reported 13.5 (8.4, 22.1)
MiBP 9.1 (7.0, 11.2) Not reported 3.1 (1.9, 5.0)
BPA 1.9 (0.79, 3.9) Not reported 2.7 (1.8, 4.3)
ang/mL, among women 20–44 years of age. bFor the conception cycle, ng/mL, specific gravity adjusted. cng/mL, not 
adjusted for creatinine. dIn the Toft et al. (2012) study MnBP was not differentiated from MiBP; it is thought that most of 
what is measured is MnBP (G Toft, personal communication).
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To further explore associations with 
shorter luteal phases, we examined the asso-
ciation of BPA and MCOP with low proges-
terone (< 2 μg/mg creatinine) in the mid-luteal 
phase. Among 423 cycles (from 154 women) 
with measured mid-luteal progesterone, 
76 (18%) had low concentrations. Elevated 
BPA was associated with reduced odds of 
low progesterone [second tertile vs. first, 
odds ratio (OR) = 0.64 (95% CI: 0.41, 1.0), 
third tertile vs. first, OR = 0.67 (95% CI: 
0.41, 1.1)]; however, it was not statistically 
significant (p = 0.24). There was no asso-
ciation for MCOP [second tertile vs. first, 
OR = 0.97 (95% CI: 0.58, 1.6), third tertile vs. 
first, OR = 1.1 (95% CI: 0.6, 2.1), p = 0.81].
Fecundability (estimated by time to clinical 
pregnancy). Estimated associations between 
tertiles of urinary phthalate metabolite concen-
trations and fecundability are depicted in 
Figure 3. A fecundability ratio < 1 indicates 
reduced fecundability for an “exposed” group. 
Neither BPA nor any of the phthalate metabo-
lites was associated with reduced fecundability 
(all p-values > 0.05). The strongest association 
was for MEHP (p = 0.18), which showed 
increased fecundability in the two highest 
tertiles of MEHP concentrations (but not with 
the other three DEHP metabolites).
A secondary analysis comparing noncon-
ception cycles with clinical conception cycles 
in the same woman was conducted. Within-
woman comparisons might be more powerful 
than between-woman comparisons if they 
eliminate extraneous between-woman vari-
ability in exposure metabolism factors. High 
concentrations of MnBP were statistically 
significantly associated with nonconception 
(linear trend p-value across tertiles = 0.01). 
The OR for conception comparing the 
second tertile of MnBP to the first tertile 
was 0.6 (95% CI: 0.3, 1.3), and for the 
third tertile compared with the first was 0.3 
(95% CI: 0.1, 0.8). Higher ΣDEHP was 
also statistically significantly associated with 
nonconception: second tertile versus first, 
OR = 0.9 (95% CI: 0.5, 1.7) and third tertile 
versus first, OR = 0.4 (95% CI: 0.2, 1.0), 
linear trend p-value across tertiles = 0.04. 
MECPP and MEHHP showed borderline 
associations with nonconception. For MECPP 
the OR comparing the second tertile with the 
first was 1.0 (95% CI: 0.5, 2.0), and for the 
third tertile was 0.5 (95% CI: 0.2, 1.1); the 
linear trend p-value across tertiles was 0.08. 
The OR for the second tertile of MEHHP 
compared with the first tertile was 0.9 
(95% CI: 0.5, 1.6) and for the third tertile 
versus the first was 0.5 (95% CI: 0.2, 1.2); the 
linear trend p-value across tertiles was 0.1.
Early pregnancy loss. None of the 
phthalate metabolites was associated with 
increased risk of early pregnancy loss (Figure 4) 
conditional on conception. Contrary to our 
a priori hypotheses, lower risk of early loss 
was seen with several urinary DEHP metabo-
lites. Higher ΣDEHP was significantly 
associated with reduced odds of early loss 
(p = 0.04), whereas the DEHP metabolite 
MEOHP showed the strongest such associa-
tion (p = 0.001); however, all metabolites of 
DEHP showed the same direction of higher 
concentrations being associated with reduced 
odds of early pregnancy loss. None of these 
compounds was related to clinical pregnancy 
loss, although we had limited power to test 
these associations (15 clinical losses; data 
not shown).
Discussion
We found that increased urinary concentra-
tions of BPA were associated with shorter 
luteal phase. Short luteal phases are less 
likely to support a conception, should one 
occur. However, we did not observe lower 
mid-luteal progesterone, increased time to 
pregnancy, or early loss with urinary BPA 
concentrations—end points that would also 
be expected to be affected by a short luteal 
phase. In adult female mice, the adverse 
effects of BPA on meiosis were strongest for 
BPA administration during oocyte growth, 
which begins 2–3 estrus cycles before ovulation 
(Hunt and Hassold 2008). We examined BPA 
in the cycle before as the exposure of interest 
to capture that potentially vulnerable time, but 
none of the outcomes was  associated with this 
lagged BPA.
The time-to-pregnancy analysis showed no 
associations of BPA or phthalate metabolites 
with fecundability. However, when noncon-
ception cycles were compared with the clinical 
conception cycle from the same woman (a 
secondary, within-woman analysis), MnBP 
and ΣDEHP were higher in the nonconcep-
tion cycles. Di-n-butyl phthalate (DnBP), 
the parent compound of MnBP, is a solvent 
Figure 2. Results of the linear mixed-model regres-
sion estimating the associations between urinary 
concentrations of phthalate metabolites and BPA 
and luteal-phase length among all study cycles 
(n = 482) (adjusted for age and BMI). Beta coef-
ficients estimate the difference in luteal-phase 
length for concentrations in the middle (white 
circles) and highest (black circles) tertiles 
compared with the lowest tertile (gray circles). 
Line segments represent the 95% CI. p-Values 
represent a 2-df test of difference among the 
tertiles. sum(DEHP) represents the molar sum of 
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0.5 0.75 Figure 3. Results of the discrete-time, time-to-event 
model estimating the associations between tertiles 
of urinary concentrations of phthalate metabolites, 
BPA, and fecundability (adjusted for age, age at 
menarche, current smoking, alcohol intake, BMI, 
caffeine consumption, and education). The graph 
shows fecundability ratios for concentrations in the 
middle (white circles) and highest (black circles) 
tertiles compared with the lowest tertile of each 
phthalate (or BPA) (gray circles). Fecundability 
ratios < 1 correspond to estimated reductions in 
fecundability. Line segments represent the 95% CI. 
p-Values represent a 2-df test of difference among 
the tertiles. sum(DEHP) represents the molar sum 
of four of the metabolites of DEHP: MEHP, MEHHP, 
MEOHP, and MECPP. The linear trend p-value for 
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used in personal care products, pharmaceu-
tical coatings, and insecticides (CDC 2015), 
and exposure to DnBP in animals was associ-
ated with reduced litter size, although there 
were no changes in estrus cyclicity (National 
Toxicology Program/National Institute of 
Environmental Health Sciences 1997).
The primary time-to-pregnancy analysis 
used the data from nearly all our study 
menstrual cycles. It compared women who 
conceived a clinical pregnancy with those 
still trying at each given menstrual cycle (a 
between-women analysis). It is possible that 
between-women differences in timing of daily 
exposures and other habits might result in 
systematic differences in first-morning urine 
concentrations among women, even assuming 
similar levels of exposure, whereas within-
woman differences between cycles might 
be more likely to reflect real cycle-specific 
 differences in exposure.
On the other hand, the within-woman 
analysis comparing nonconception to concep-
tion cycles is based on a small, select sample. 
Women in this analysis had at least one 
nonconception cycle and then had conceived 
a clinical pregnancy during the study. Thus, 
the most fecund (women who conceived in 
the first cycle), and the least fecund [women 
who never conceived or conceived after leaving 
the study (usually after cycle 6)] were excluded 
from the within-woman analysis. Given the 
short half-life of phthalates and BPA, and the 
likely episodic nature of the exposures, further 
studies that can examine both within-woman 
and between-women differences will be 
needed. We know of only one other between-
women analysis of phthalates and BPA and 
fecundability (Buck Louis et al. 2014). This 
study found no association of women’s BPA 
and phthalate metabolite urinary concentra-
tions with fecundability, but did find reduced 
fecundability with several phthalate metabolites 
measured in their male partners.
A previous study of Danish women 
reported increased risk of early pregnancy 
loss with higher urinary concentrations of the 
DEHP metabolite MEHP (OR = 41 (95% 
CI: 4.5, 370) (Toft et al. 2012). This asso-
ciation was not present in our study (highest 
tertile vs. lowest: OR = 0.5 (95% CI: 0.2, 1.3) 
though we had approximately 100% power to 
detect the reported OR of 41. On the contrary, 
ΣDEHP was associated with reduced odds of 
early pregnancy loss. It is possible that exposure 
to DEHP may cause losses to occur earlier, 
before the detection of hCG in maternal urine, 
resulting in a net decrease in the frequency of 
observed early loss.
The findings in the Toft study should be 
considered critically (Toft et al. 2012). During 
this study, women were enrolled when they 
discontinued birth control and were followed 
prospectively for 6 months or until they 
conceived a clinical pregnancy. The women 
collected daily urine specimens for the first 
10 days of the menstrual cycle. Of the 430 
women enrolled, 77 did not collect any urine 
samples because they conceived in the first 
menstrual cycle. The final sample size of Toft 
et al. (2012) is slightly smaller than ours (128 
women who had 32 early pregnancy losses), 
and it lacked samples from the highly fertile 
couples who conceived in the first cycle. As 
Toft et al. (2012) noted, the proportion of 
pregnancies ending in early loss in the lowest 
tertile of urinary MEHP concentration was 
3%, whereas the overall rate of early loss was 
25%, similar to that of the EPS (24%). Thus, 
the “high” loss in the highest MEHP tertile 
was attributable to an extremely low loss rate 
in the referent category. However, the reported 
urinary concentrations of MEHP were higher 
in the Danish women in 1992–1994 than in 
the North Carolina women in 1982–1986, 
though the Danish women’s urinary concen-
trations of MEHHP and MEOHP were 
similar to those in our study (Table 2). The 
similar urinary concentrations of these oxida-
tive metabolites of DEHP (another oxidative 
metabolite, MECPP, was not measured in the 
Danish cohort) in the Danish women and in 
the EPS women suggests comparable expo-
sures to the parent compound DEHP (Enke 
et al. 2013). Reasons for the three-times-higher 
concentrations of MEHP among the Danish 
women are unknown.
The strengths of our study include 
hormonally defined ovulation and early 
pregnancy loss, detailed prospective time-to-
pregnancy data, and a study cohort comprising 
naturally cycling women with no known 
fertility problems. The use of pooled daily 
urine specimens from three time points in each 
menstrual cycle serves to decrease measurement 
variability and improve precision for assessing 
exposure effects, given the short half-life of 
phthalates and BPA. To our knowledge, this 
is the first study to estimate exposure for each 
menstrual cycle of interest rather than use an 
estimate based on a single-day measure.
Our study also has weaknesses. We used 
mostly Monday-morning urine specimens 
because women collected two samples every 
Monday, so that sample was usually available 
and relatively untouched. However, to the 
extent that phthalate exposures from cosmetics 
may vary across the days of the week, our 
Monday samples may be unrepresentative. 
The storage containers for EPS urines were 
unlikely to be sources of contamination by 
exogenous BPA or phthalates, but we cannot 
completely rule out contamination or degra-
dation of the urine specimen. If contamina-
tion occurred either during urine transfer or 
processing, its impact would be less problem-
atic for phthalates than for BPA because we 
measured phthalate metabolites and not the 
parent compounds. Other studies that report 
contamination show much higher levels of 
urinary BPA [7 ng/mL compared with our 
median of 2.7 ng/mL (Guidry et al. 2015)], 
which further suggests that widespread BPA 
contamination of our samples is unlikely. We 
did not thoroughly explore the associations 
between phthalate metabolites and BPA with 
hormone levels because hormone measures 
were done in restricted time windows and only 
extensively for a subset of the cycles. Although 
unique, our study is relatively small, incorpo-
rating data from 221 women. These women 
were healthy volunteers, which may limit 
generalizability of our findings. Finally, given 
the number of statistical analyses performed, at 
least some of the positive associations reported 
may have arisen by chance.
A final strength of the study is that 
samples were collected at a time when the U.S. 
population’s exposures to BPA and phthal-
ates were generally higher than they are now. 
Figure 4. Results of the logistic regression esti-
mating the associations between urinary concen-
trations of phthalate metabolites and BPA and 
early pregnancy loss (adjusted for age, current 
smoking, alcohol intake, BMI, caffeine consump-
tion, education, and season). The two estimates 
shown for each metabolite are estimates for the 
middle (white circles) and highest (black circles) 
tertiles of phthalate or BPA urinary concentration, 
relative to the lowest tertile (gray circles). Line 
segments represent the 95% CI. p-Values repre-
sent a 2-df test of difference among the tertiles. 
sumDEHP represents the molar sum of four of the 
metabolites of DEHP: MEHP, MEHHP, MEOHP, 
and MECPP. Linear trend p-values: MEHHP = 0.14, 
MEOHP  =  0.05, MCPP  =  0.17, MECPP  =  0.10, 
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Urinary concentrations of DEHP metabo-
lites from a recent  nationally  representative 
sample of U.S. reproductive-age women 
(2009–2010 NHANES) are lower than in 
the EPS, reflecting the reported decline in 
exposure of certain phthalates in the United 
States over time (Zota et al. 2014). Other 
more recent studies also show lower urinary 
levels than found in our study. Data from the 
Longitudinal Investigation of Fertility and 
the Environment cohort found lower levels 
of all phthalate metabolites (except MiBP) 
compared with our cohort (Buck Louis et al. 
2014). Other U.S. cohorts from the Midwest 
and California (1999–2005) (Kobrosly et al. 
2014), southwest Ohio (2003–2006) (Yolton 
et al. 2011), and Massachusetts (2004–2009) 
(Braun et al. 2012) report lower levels of BPA 
and phthalate metabolites compared with the 
EPS women, except for MiBP, which was 
higher. The Norwegian Mother and Child 
Cohort Study (MoBa) reported lower levels 
of phthalates compared with the EPS women 
except for MiBP and MEHP (Ye et al. 2009). 
The Generation R study reported lower levels 
of BPA and all phthalates except for MiBP (Ye 
et al. 2008).
Conclusions
To our knowledge, this is the first study to 
examine the association between urinary 
concentrations of BPA and phthalate metabo-
lites with follicular- and luteal-phase length. 
Previous data on fecundability and early loss 
are limited to a single study each (Buck Louis 
et al. 2014; Toft et al. 2012). The within-
woman analysis of nonconception compared 
with conception cycles raises questions about 
possible adverse effects of exposure to DEHP 
and DnBP, the parent compound of MnBP. 
However, these findings need confirmation 
because none of the urinary concentrations of 
phthalate metabolites or BPA were associated 
with decreased fecundability in the cohort as a 
whole. In our analyses we found little evidence 
to suggest that the urinary concentrations of 
phthalate metabolites we measured or BPA 
are associated with follicular-phase length 
or increased risk of early pregnancy loss, but 
there was an association between ΣDEHP and 
reduced risk of early loss. Urinary concentra-
tions of BPA and MCOP may be associated 
with a shorter luteal phase, and this should be 
confirmed in future studies.
RefeRences
Baird DD, Saldana TM, Nepomnaschy PA, Hoppin JA, 
Longnecker MP, Weinberg CR, et al. 2010. Within-
person variability in urinary phthalate metabolite 
concentrations: measurements from specimens 
after long-term frozen storage. J Expo Sci Environ 
Epidemiol 20:169–175.
Baird DD, Weinberg CR, Wilcox AJ, McConnaughey DR, 
Musey PI. 1991. Using the ratio of urinary oestrogen 
and progesterone metabolites to estimate day of 
ovulation. Stat Med 10:255–266.
Bai rd  DD,  Weinberg  CR,  Zhou H,  Kamel  F , 
McConnaughey DR, Kesner JS, et  al. 1999. 
Preimplantation urinary hormone profiles and the 
probability of conception in healthy women. Fertil 
Steril 71:40–49.
Baird DD, Wilcox AJ, Weinberg CR. 1986. Use of time 
to pregnancy to study environmental exposures. 
Am J Epidemiol 124:470–480.
Berger RG, Foster WG, deCatanzaro D. 2010. Bisphenol-A 
exposure during the period of blasto cyst implantation 
alters uterine morphology and perturbs measures of 
estrogen and progesterone receptor expression in 
mice. Reprod Toxicol 30:393–400.
Berger RG, Hancock T, deCatanzaro D. 2007. Influence 
of oral and subcutaneous bisphenol-A on intra-
uterine implantation of fertilized ova in insemi-
nated female mice. Reprod Toxicol 23:138–144.
Berger RG, Shaw J, deCatanzaro D. 2008. Impact of acute 
bisphenol-A exposure upon intrauterine implantation 
of fertilized ova and urinary levels of progesterone 
and 17β-estradiol. Reprod Toxicol 26:94–99.
Braun JM, Smith KW, Williams PL, Calafat AM, 
Berry K, Ehrlich S, et al. 2012. Variability of urinary 
phthalate metabolite and bisphenol A concentra-
tions before and during pregnancy. Environ Health 
Perspect 120:739–745; doi:10.1289/ehp.1104139.
Buck Louis GM, Sundaram R,  Sweeney AM, 
Schisterman EF, Maisog J, Kannan K. 2014. Urinary 
bisphenol A, phthalates, and couple fecundity: 
the Longitudinal Investigation of Fertility and the 
Environment (LIFE) Study. Fertil Steril 101:1359–1366.
Can A, Semiz O, Cinar O. 2005. Bisphenol-A induces 
cell cycle delay and alters centrosome and 
spindle microtubular organization in oocytes 
during meiosis. Mol Hum Reprod 11:389–396.
CDC (Centers for Disease Control and Prevention). 
2015. Fourth National Report on Human Exposure 
to Environmental Chemicals, Updated Tables, 
February 2015. Atlanta, GA:CDC. Available: http://
www.cdc.gov/biomonitoring/pdf/FourthReport_
U p d a t e d T a b l e s _ F e b 2 0 1 5 . p d f  [ a c c e s s e d 
22 January 2016].
Ehrlich S, Williams PL, Missmer SA, Flaws JA, 
Ye X, Calafat AM, et al. 2012. Urinary bisphenol 
A concentrations and early reproductive health 
outcomes among women undergoing IVF. Hum 
Reprod 27:3583–3592.
Enke U, Schleussner E, Pälmke C, Seyfarth  L, 
Koch HM. 2013. Phthalate exposure in pregnant 
women and newborns—the urinary metabolite 
excretion pattern differs distinctly. Int J Hyg 
Environ Health 216:735–742.
Fenster L, Quale C, Waller K, Windham GC, Elkin EP, 
Benowitz N, et al. 1999. Caffeine consumption and 
menstrual function. Am J Epidemiol 149:550–557.
Ferguson KK, Cantonwine DE, Rivera-González LO, 
Loch-Caruso R, Mukherjee B, Anzalota Del 
Toro LV, et al. 2014. Urinary phthalate metabolite 
associations with biomarkers of inflammation and 
oxidative stress across pregnancy in Puerto Rico. 
Environ Sci Technol 48:7018–7025.
Ferguson KK, Loch-Caruso R, Meeker JD. 2011. 
Urinary phthalate metabolites in relation to 
biomarkers of inflammation and oxidative stress: 
NHANES 1999–2006. Environ Res 111:718–726.
Ferguson KK, Loch-Caruso R, Meeker JD. 2012. 
Exploration of oxidative stress and inflammatory 
markers in relation to urinary phthalate metabolites: 
NHANES 1999–2006. Environ Sci Technol 46:477–485.
Galbraith RF. 2014. Trigonometric Regression. Wiley 
StatsRef: Statistics Reference Online. Available: http://
onlinelibrary.wiley.com/doi/10.1002/9781118445112.
stat05785/full [accessed 22 January 2016].
Gray LE Jr, Laskey J, Ostby J. 2006. Chronic di-n-butyl 
phthalate exposure in rats reduces fertility and 
alters ovarian function during pregnancy in female 
Long Evans hooded rats. Toxicol Sci 93:189–195.
Greenwald GS, Terranova PF. 1988. Follicular selection 
and its control. In: The Physiology of Reproduction 
(Knobil E, Neill JD, eds). New York:Raven Press, 
387–446.
Guidry VT, Longnecker MP, Aase H, Eggesbø  M, 
Zeiner  P, Reichborn-Kjennerud T, et  al. 2015. 
Measurement of total and free urinary phenol 
and paraben concentrations over the course of 
pregnancy: assessing reliability and contamination 
of specimens in the Norwegian Mother and Child 
Cohort Study. Environ Health Perspect 123:705–711; 
doi:10.1289/ehp.1408325.
Hauser R, Calafat AM. 2005. Phthalates and human 
health. Occup Environ Med 62:806–818.
Hunt PA, Hassold TJ. 2008. Human female meiosis: what 
makes a good egg go bad? Trends Genet 24:86–93.
Hunt PA, Koehler KE, Susiarjo M, Hodges CA, Ilagan A, 
Voigt RC, et al. 2003. Bisphenol A exposure causes 
meiotic aneuploidy in the female mouse. Curr Biol 
13:546–553.
Jukic AMZ, Weinberg CR, Baird DD, Wilcox AJ. 2007. 
Lifestyle and reproductive factors associated 
with follicular phase length. J Womens Health 
(Larchmt) 16:1340–1347.
Kay VR, Chambers C, Foster WG. 2013. Reproductive 
and developmental effects of phthalate diesters in 
females. Crit Rev Toxicol 43:200–219.
Kobrosly RW, Evans S, Miodovnik A, Barrett ES, 
Thurston SW, Calafat AM, et al. 2014. Prenatal 
phthalate exposures and neurobehavioral devel-
opment scores in boys and girls at 6–10 years 
of age. Environ Health Perspect 122:521–528; 
doi:10.1289/ehp.1307063.
Lenie S, Cortvrindt R, Eichenlaub-Ritter U, Smitz J. 
2008. Continuous exposure to bisphenol A during 
in vitro follicular development induces meiotic 
abnormalities. Mutat Res 651:71–81.
Machtinger R, Hauser R, Combelles C, Racowsky C. 
2011. The impact of bisphenol A (BPA) on human 
oocyte meiotic maturation. Fertil Steril 96:S7.
Mok-Lin E, Ehrlich S, Williams PL, Petrozza J, Wright DL, 
Calafat AM, et al. 2010. Urinary bisphenol A concen-
trations and ovarian response among women 
undergoing IVF. Int J Androl 33:385–393.
Muhlhauser A, Susiarjo M, Rubio C, Griswold J, 
Gorence G, Hassold T, et al. 2009. Bisphenol A 
effects on the growing mouse oocyte are influ-
enced by diet. Biol Reprod 80(5):1066–1071.
National Toxicology Program/National Institute of 
Environmental Health Sciences. 1997. Reproductive 
toxicology. Di-n-butylphthalate, rats. Environ 
Health Perspect 105(suppl 1):249–250.
NCHS (National Center for Health Statistics). 2011a. 
2009–2010 Data Documentation, Codebook, and 
Frequencies: Environmental Phenols (EPH_E). 
Available: http://wwwn.cdc.gov/Nchs/Nhanes/2009-
2010/EPH_F.htm [accessed 22 June 2015].
NCHS. 2011b. 2009–2010 Data Documentation, 




Nepomnaschy PA, Baird DD, Weinberg CR, Hoppin JA, 
Longnecker MP, Wilcox AJ. 2009. Within-person 
variability in urinary bisphenol A concentrations: 
measurements from specimens after long-term 
frozen storage. Environ Res 109:734–737.
Silva MJ, Samandar E, Preau JL Jr, Reidy JA, 
Needham LL, Calafat AM. 2007. Quantification of 22 
phthalate metabolites in human urine. J Chromatogr 
B Analyt Technol Biomed Life Sci 860:106–112.
Jukic et al.
328 volume 124 | number 3 | March 2016 • Environmental Health Perspectives
Takai Y, Tsutsumi O, Ikezuki Y, Kamei Y, Osuga Y, 
Yano T, et al. 2001. Preimplantation exposure to 
bisphenol  A advances postnatal development. 
Reprod Toxicol 15:71–74.
Tetz LM, Cheng AA, Korte CS, Giese RW, Wang P, 
Harris C, et al. 2013. Mono-2-ethylhexyl phthalate 
induces oxidative stress responses in human 
placental cells in vitro. Toxicol Appl Pharmacol 
268:47–54.
Toft G, Jönsson BA, Lindh CH, Jensen TK, Hjollund NH, 
Vested A, et al. 2012. Association between preg-
nancy loss and urinary phthalate levels around 
the time of conception. Environ Health Perspect 
120:458–463; doi:10.1289/ehp.1103552.
Tsutsui T, Tamura Y, Yagi E, Hasegawa K, Takahashi M, 
Maizumi N, et al. 1998. Bisphenol-A induces cellular 
transformation, aneuploidy and DNA adduct forma-
tion in cultured Syrian hamster embryo cells. Int J 
Cancer 75:290–294.
Weinberg CR, Moledor E, Baird DD, Wilcox AJ. 1994. Is 
there a seasonal pattern in risk of early pregnancy 
loss? Epidemiology 5:484–489.
Weinberg CR, Wilcox AJ. 2008. Methodologic issues 
in reproductive epidemiology. In:  Modern 
Epidemiology (Rothman KJ, Greenland S, Lash TL, 
eds). 3rd ed. Philadelphia, PA:Lippincott Williams & 
Wilkins, 640.
Weinberg CR, Wilcox AJ, Baird DD. 1989. Reduced 
fecundability in women with prenatal exposure to 
cigarette smoking. Am J Epidemiol 129:1072–1078.
Wilcox A, Weinberg C, Baird D. 1988a. Caffeinated bever-
ages and decreased fertility. Lancet 2:1453–1456.
Wilcox AJ, Weinberg CR, Baird DD. 1990. Risk factors 
for early pregnancy loss. Epidemiology 1:382–385.
Wilcox AJ, Weinberg CR, Baird DD. 1995. Timing 
of sexual intercourse in relation to ovulation – 
effects on the probability of conception, survival 
of the pregnancy, and sex of the baby. New Eng J 
Med 333(23):1517–1521.
Wilcox AJ, Weinberg CR, O’Connor JF, Baird DD, 
Schlatterer JP, Canfield RE, et al. 1988b. Incidence 
of early loss of pregnancy. N Engl J Med 
319:189–194.
Windham GC,  E lk in  E ,  Fenster  L ,  Wal ler  K , 
Anderson  M, Mitchell PR, et  al. 2002. Ovarian 
hormones in premenopausal women: variation by 
demographic, reproductive and menstrual cycle 
characteristics. Epidemiology 13:675–684.
Yamasaki K, Okuda H, Takeuchi T, Minobe Y. 2009. 
Effects of in utero through lactational exposure to 
dicyclohexyl phthalate and p,p’-DDE in Sprague–
Dawley rats. Toxicol Lett 189:14–20.
Ye X, Kuklenyik Z, Needham LL, Calafat AM. 
2005. Automated on-line column-switching 
HPLC-MS/MS method with peak focusing for the 
determination of nine environmental phenols in 
urine. Anal Chem 77:5407–5413.
Ye X, Pierik FH, Angerer J, Meltzer HM, Jaddoe VW, 
Tiemeier H, et al. 2009. Levels of metabolites of 
organophosphate pesticides, phthalates, and 
bisphenol  A in pooled urine specimens from 
pregnant women participating in the Norwegian 
Mother and Child Cohort Study (MoBa). Int J Hyg 
Environ Health 212:481–491.
Ye X, Pierik FH, Hauser R, Duty S, Angerer J, Park MM, 
et al. 2008. Urinary metabolite concentrations of 
organophosphorous pesticides, bisphenol A, and 
phthalates among pregnant women in Rotterdam, 
the Netherlands: the Generation R study. Environ 
Res 108(2):260–267.
Yolton K, Xu Y, Strauss D, Altaye M, Calafat AM, 
Khoury J. 2011. Prenatal exposure to bisphenol A 
and phthalates and infant neurobehavior. 
Neurotoxicol Teratol 33:558–566.
Zota AR, Calafat AM, Woodruff TJ. 2014. Temporal 
trends in phthalate exposures: findings from the 
National Health and Nutrition Examination Survey, 
2001–2010. Environ Health Perspect 122:235–241; 
doi:10.1289/ehp.1306681.
